🇺🇸 Azacitidine Injection in United States
46 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 46
Most-reported reactions
- Neutropenia — 7 reports (15.22%)
- Pancytopenia — 7 reports (15.22%)
- Respiratory Failure — 5 reports (10.87%)
- Confusional State — 4 reports (8.7%)
- Febrile Neutropenia — 4 reports (8.7%)
- Injection Site Erythema — 4 reports (8.7%)
- Neutropenic Sepsis — 4 reports (8.7%)
- Pleural Effusion — 4 reports (8.7%)
- Septic Shock — 4 reports (8.7%)
- Acute Febrile Neutrophilic Dermatosis — 3 reports (6.52%)
Other Oncology approved in United States
Frequently asked questions
Is Azacitidine Injection approved in United States?
Azacitidine Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Azacitidine Injection in United States?
Ascentage Pharma Group Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.